Literature DB >> 9692706

Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy.

C A Stewart1, B Termanini, V E Sutliff, J Serrano, F Yu, F Gibril, R T Jensen.   

Abstract

BACKGROUND: Gastric acid secretion is important for absorption of dietary non-haem iron, and iron deficiency is common in gastric hyposecretory states such as after gastric resection. It is not known if prolonged, continuous treatment with potent acid suppressants such as omeprazole will lead to iron deficiency or lower body iron stores. AIM: To assess iron stores and the occurrence of iron deficiency anaemia in patients with Zollinger-Ellison syndrome (ZES) treated long-term with gastric antisecretory drugs.
METHODS: One hundred and nine patients with ZES but without previous gastric resections were studied. All patients underwent assessment of acid control on antisecretory agents, determination of tumour extent, evaluation of haematological parameters (Hct, haemoglobin, WBC, MCV, MCHC), and determination of serum iron parameters (iron, ferritin, transferrin, iron/ transferrin ratio). Acid control values for the last 4 years were reviewed, the presence or absence of acid hyposecretion determined using three different criteria and this result correlated with haematological and iron parameters.
RESULTS: Eighty-nine patients were taking omeprazole, nine patients were taking histamine H2-antagonists and 11 patients were taking no drugs following curative resection. The mean duration of omeprazole treatment was 5.7 years (range 0.7-12.5 years) and total duration of any treatment was 10.1 years (range 0.7-21 years). Acid hyposecretion was present by at least one criterion in 45% of patients. There were no significant differences between patients with or without acid hyposecretion, taking or not taking omeprazole, having different durations of omeprazole treatment or different durations of total time receiving any antisecretory treatment, for any serum iron parameter, haematological parameter, or for the frequency of iron deficiency. Males and females did not differ in percentage with low ferritin levels or percentage with iron deficiency.
CONCLUSIONS: Continuous treatment with omeprazole for 6 years or continuous treatment with any gastric antisecretory drug for 10 years does not cause decreased body iron stores or iron deficiency. These results suggest that, in contrast to recent results which show yearly monitoring of vitamin B12 in such patients is needed, such monitoring for iron parameters is not necessary.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692706     DOI: 10.1046/j.1365-2036.1998.00274.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  34 in total

1.  Impact of Acid Suppression Therapy on Iron Supplementation in the Pediatric Intensive Care Unit.

Authors:  Emily Hailstone; Sheryl Falkos; Rosa Vidal; K Ashley Jones; Philippe R Gaillard; Shirley Fan; Allison M Chung
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

2.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

3.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

Review 4.  Potential adverse effects of proton pump inhibitors.

Authors:  Gregory A Coté; Colin W Howden
Journal:  Curr Gastroenterol Rep       Date:  2008-06

5.  Prevalence and predictive factors for gastrointestinal pathology in young men evaluated for iron deficiency anemia.

Authors:  Dan Carter; Gad Levi; Dorit Tzur; Ben Novis; Benjamin Avidan
Journal:  Dig Dis Sci       Date:  2012-11-29       Impact factor: 3.199

Review 6.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

7.  Circulating gastrin is increased in hemochromatosis.

Authors:  Kelly A Smith; Suzana Kovac; Gregory J Anderson; Arthur Shulkes; Graham S Baldwin
Journal:  FEBS Lett       Date:  2006-10-18       Impact factor: 4.124

Review 8.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

9.  Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications.

Authors:  Joel J Heidelbaugh
Journal:  Ther Adv Drug Saf       Date:  2013-06

Review 10.  Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective.

Authors:  Amy Zhu; Marc Kaneshiro; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.